Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 20/20 | 0.80 |
| ▸ | CHUK | O15111 | 6/20 | 0.80 |
| ▸ | BTK | Q06187 | 2/20 | 0.61 |
| ▸ | CSF1R | P07333 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4688449 | 0.90 | IKBKB (0.98) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL4688652 | 0.89 | IKBKB (0.80) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL4687061 | 0.89 | IKBKB (0.80) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL3796938 | 0.89 | IKBKB (1.00) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL4686154 | 0.87 | IKBKB (0.67) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL621955 | 0.87 | IKBKB (0.84) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL28763733 | 0.87 | IKBKB (0.77) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL621954 | 0.87 | IKBKB (1.00) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL4689143 | 0.86 | IKBKB (0.75) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL4688211 | 0.86 | IKBKB (0.75) | IKBKBCHUKBTKCSF1RAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273886-B2 | For therapy and prophylaxis of clotting disorders; useful for inhibiting serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein | GENENTECH, INC. (US) | 2007-09-25 | — | — | US | claimed |
| US-7858796-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858796-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858796-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| EP-1703905-B1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20070254873-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070254873-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070254873-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| CN-101060842-A | Chemical compounds | GLAXO GROUP LTD (GB) | 2007-10-24 | — | — | CN | disclosed |
| EP-1793826-A2 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-06-13 | — | — | EP | disclosed |
| CN-1933830-A | Indole derivatives and their use as kinase inhibitors, in particular IKK2 inhibitors | SMITHKLINE BEECHAM CORP (US) | 2007-03-21 | — | — | CN | disclosed |
| WO-2006034317-A2 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254873-A1 | Chemical Compounds | IKBKG, NFKBIA, RELA | IKBKB 5/4885CHUK 9/4885BTK 386/4885 |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | NFKBIA, IKBKB, IDO2 | IKBKB 2/4885CHUK 6/4885BTK 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.